Bioactive Recombinant Human Oncostatin M for NMR-Based Screening in Drug Discovery by Mass, Olga A. et al.
Boise State University 
ScholarWorks 
Biomolecular Research Center Publications and 
Presentations Biomolecular Research Center 
8-10-2021 
Bioactive Recombinant Human Oncostatin M for NMR-Based 
Screening in Drug Discovery 
Olga A. Mass 
Boise State University 
Joseph Tuccinardi 
Boise State University 
Luke Woodbury 
Boise State University 
Cody L. Wolf 
Boise State University 
Bri Grantham 
Boise State University 
See next page for additional authors 
Publication Information 
Mass, Olga A.; Tuccinardi, Joseph; Woodbury, Luke; Wolf, Cody L.; Grantham, Bri; Holdaway, Kelsey; Pu, 
Xinzhu; King, Matthew D.; Warner, Don L.; Jorcyk, Cheryl L.; and Warner, Lisa R.. (2021). "Bioactive 
Recombinant Human Oncostatin M for NMR-Based Screening in Drug Discovery". Scientific Reports, 11, 
16174. https://doi.org/10.1038/s41598-021-95424-6 
These authors contributed equally: Olga A. Mass and Joseph Tuccinardi. 
Authors 
Olga A. Mass, Joseph Tuccinardi, Luke Woodbury, Cody L. Wolf, Bri Grantham, Kelsey Holdaway, Xinzhu 
Pu, Matthew D. King, Don L. Warner, Cheryl L. Jorcyk, and Lisa R. Warner 
This article is available at ScholarWorks: https://scholarworks.boisestate.edu/brc_facpubs/37 
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:16174  | https://doi.org/10.1038/s41598-021-95424-6
www.nature.com/scientificreports
Bioactive recombinant human 
oncostatin M for NMR‑based 
screening in drug discovery
Olga A. Mass1,5, Joseph Tuccinardi2,5, Luke Woodbury1, Cody L. Wolf3,4, Bri Grantham1, 
Kelsey Holdaway2, Xinzhu Pu1,3, Matthew D. King2,3, Don L. Warner2,3, Cheryl L. Jorcyk3,4 & 
Lisa R. Warner1,2,3*
Oncostatin M (OSM) is a pleiotropic, interleukin‑6 family inflammatory cytokine that plays an 
important role in inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, 
and cancer progression and metastasis. Recently, elevated OSM levels have been found in the serum 
of COVID‑19 patients in intensive care units. Multiple anti‑OSM therapeutics have been investigated, 
but to date no OSM small molecule inhibitors are clinically available. To pursue a high‑throughput 
screening and structure‑based drug discovery strategy to design a small molecule inhibitor of OSM, 
milligram quantities of highly pure, bioactive OSM are required. Here, we developed a reliable 
protocol to produce highly pure unlabeled and isotope enriched OSM from E. coli for biochemical 
and NMR studies. High yields (ca. 10 mg/L culture) were obtained in rich and minimal defined media 
cultures. Purified OSM was characterized by mass spectrometry and circular dichroism. The bioactivity 
was confirmed by induction of OSM/OSM receptor signaling through STAT3 phosphorylation in 
human breast cancer cells. Optimized buffer conditions yielded 1H, 15N HSQC NMR spectra with 
intense, well‑dispersed peaks. Titration of 15N OSM with a small molecule inhibitor showed chemical 
shift perturbations for several key residues with a binding affinity of 12.2 ± 3.9 μM. These results 
demonstrate the value of bioactive recombinant human OSM for NMR‑based small molecule 
screening.
Oncostatin M (OSM) is a pleiotropic inflammatory cytokine and a member of the interleukin-6 (IL-6)  family1. 
OSM plays physiological roles in wound  healing2, viral immune  response3, hematopoiesis and liver  homeostasis4, 
lipid  metabolism5, and bone  development6. It also is important in chronic inflammatory diseases such as inflam-
matory bowel  disease7 and rheumatoid  arthritis8. Most recently, OSM was identified as one of the proteins that 
are found at high levels in the serum of COVID-19 intensive care unit (ICU) patients that correlated with disease 
severity, potentially pointing to a role for OSM in cytokine storm reactions during SARS-CoV-2  infections9.
OSM also plays an important role in cancer invasion and metastasis, specifically in the context of breast 
 cancer10, hepatocellular  cancer11, and prostate  carcinomas12, to name a few. Our work in defining the role of OSM 
in breast cancer metastasis has shown that OSM signaling increases tumor cell detachment in a COX2-dependent 
 fashion13, epithelial-mesenchymal  transition14, and the invasive potential of human and mouse mammary car-
cinoma  cells13–15. We have further shown that OSM promotes the expression of proteases that can contribute 
to  metastasis14 as well as other metastasis-related proangiogenic proteins such as vascular endothelial growth 
factor (VEGF)16 and hypoxia-inducible factor-1α (HIF1α)16,17. Finally, we have demonstrated that OSM induces 
osteolytic bone metastases in vivo18, as well as lung and other metastases in two different mouse models of breast 
 cancer19. Moreover, increased expression of both OSM and the OSM receptor (OSMRβ) have been correlated 
with increased recurrence of tumors and decreased survival in breast cancer  patients18,20.
The ability of OSM to stimulate multiple signaling pathways is responsible for the observed pleiotropic effects 
of OSM in various diseases as well as biological processes. Extracellular OSM stimulates signal transduction 
through interactions with two unique receptors: the leukemia inhibitory factor receptor (LIFR) and the OSM 
receptor (OSMR). OSM binds to the heterodimeric OSMR, which is comprised of OSMRβ and gp130, with 
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higher affinity than it binds the heterodimeric LIFR, which consists of **LIFRβ and the common  gp13021. For 
example, ERK1/2, PI3K, and STAT1/3 can be activated by OSM binding the LIFR or OSMR, but only signaling 
through the OSMR can activate STAT5, p38, JNK, and possibly PKC-δ and  STAT622.
OSM has been identified as a potential therapeutic target for treatment of inflammatory diseases. Multiple 
approaches to inhibit OSM signaling have been investigated, including RNA  aptamers23 and antibody  therapies24. 
Specific inhibition of OSM-OSMRβ interactions by neutralizing antibodies targeting the OSM receptor subunit 
OSMRβ has led to reduced lethality in a mouse model of inflammatory  cardiomyopathy25 and reduced invasion, 
angiogenesis, and metastasis in squamous cell  carcinoma26.
Several challenges exist with the current antibody therapy approach. The slow clearance of antibody thera-
pies from circulation exacerbates this potential issue, especially in cases where a patient sustains an injury that 
requires an OSM-induced inflammatory response, requires surgical intervention, or contracts an infection. 
Specifically, GSK2330811 was found to have a plasma elimination half-life of 19–25  days24, while small molecule 
drugs generally have half-lives on the order of hours, which can be of significant clinical benefit in the case of 
drugs that suppress the inflammatory  response27. Beyond offering cost advantages for development, there are 
multiple logistical advantages to orally bioavailable small molecule therapies. These include longer shelf-life and 
greater stability that precludes the need for refrigeration, which is especially important in rural and other areas 
that may also have limited experience or infrastructure for parenteral drug  administration27. A small molecule 
inhibitor of the OSM-OSMRβ interaction would provide specific disruption of the OSM-specific cell signaling 
pathway, and a structure-based rational design of small molecule inhibitors uniquely targeting the OSM-OSMRβ 
interaction could provide a potential treatment for a wide variety of OSM-mediated diseases. Given the exten-
sive role of OSM in inflammatory diseases, cancer, and the potential role of OSM in COVID-19, small molecule 
inhibitors of OSM could provide a much-needed tool for clinicians.
Although the structure of the OSM-OSMRβ complex remains unsolved, a crystal structure of OSM and 
alanine scanning assays have provided key insights into how OSM binds to the OSMRβ28. The human OSM 
gene is translated as a 252 amino acid polypeptide, where the first 25 residues are an extracellular secretory 
signal  peptide29, and the C-terminal 31 residues are proteolytically cleaved to yield an active 196 residue mature 
 protein30 (Fig. 1A). OSM is a four-helix bundle comprised of helices A, B, C and D that are arranged in an up-
up-down-down configuration, joined by loops AB, BC and CD and anchored by two intramolecular disulfide 
bonds (Figs. 1B and 1C). Two receptor binding sites (II and III) are noted in OSM (Fig. 1C). Site II residues 
Gln20, Gln16, Gly120, and Asn124 are important for OSM interaction with the gp130 subunit of the  OSMR28. 
The N-terminal region of helix D contains protruding Phe160 and Lys163 residues that make up an FXXK motif 
in binding site III that has been shown to be essential for OSM interaction with LIFR, LIFR/gp130, and OSMR/
gp130 as measured by receptor binding and cell survival  assays28. The FXXK motif is thought to be especially 
important for direct interaction of OSM with the OSMRβ subunit of the  OSMR31.
Figure 1.  OSM structure overview. (A) Schematic representation of the OSM gene product. Signal peptide 
and propeptide are removed post-translationally. (B) Domain architecture of OSM showing the four helices A, 
B, C and D and disulfide bonds. The Loop CD and the C-terminus were not observed in the crystal  structure28 
and are colored gray. (C) Cartoon representation of OSM from PDBID 1EVS, Site II, Site III, and disulfides 
are shown as sticks, colored according to domain architecture. (D) Schematic representation of the expression 
constructs used in this study. A Tobacco Etch Virus protease site (scissors) was engineered into pD441-NH 
(6-His) and pD441-MBP (maltose binding protein) fusion constructs that included OSM 1–187.
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A structure-guided approach to designing chemical inhibitors for OSM is needed to specifically inhibit 
the OSM signaling pathway. Solution nuclear magnetic resonance (NMR) spectroscopy is a particularly use-
ful method for structure-based drug  discovery32,33. However, NMR is an inherently insensitive technique that 
requires milligram quantities of isotopically labeled proteins. Thus, a reliable protocol to produce large quantities 
of highly pure, bioactive recombinant human OSM (rhOSM) is required to fully employ an NMR based structure-
based drug design approach and to screen for small molecule ligands in the pursuit of small molecule inhibitors.
Here, we report an efficient protocol for the expression of recombinant, soluble, isotopically labeled rhOSM 
in high yield and purity in a bacterial expression platform. Prior work by Nguyen et al., described the production 
of recombinant human OSM using MBP-tagged OSM in SHuffle E. coli cells. We detail here our independent 
findings, including additional examination of the effects of growth medium, cell strains, temperature, construct 
design, and further purification for the production of rhOSM with isotope enrichment. Bioactivity of the rhOSM 
was comparable to commercially available recombinant human OSM (chOSM) in human breast cancer cells as 
determined by an enzyme-linked immunosorbent assay (ELISA), which detected phosphorylation of STAT3. 
Optimized buffer conditions for NMR studies were identified using differential scanning fluorimetry (DSF). The 
resulting NMR spectra showed an increase in the intensity of spectral peaks consistent with enhanced solubility 
of the rhOSM in conditions suitable for structure-based drug development. Moreover, we demonstrate the utility 
of the isotopically enriched rhOSM with 1H, 15N HSQC NMR titrations with, to the best of our knowledge, the 
first small molecule ligand determined to directly bind to OSM in binding site III. The results presented herein 
suggest that bioactive rhOSM can be efficiently produced and used for structure-based drug design.
Results
Expression and purification of rhOSM. The construct of rhOSM we have chosen to work with is a frag-
ment of OSM encoding residues 1–187. This fragment was chosen for three reasons: (1) it has the same sequence 
used in the crystal structure and therefore supports a structure-based drug design  approach28, (2) the binding 
site we are interrogating with small molecules is distal to the C-terminus, and (3) the C-terminus of the mature 
protein, comprising residues 188–196, does not contribute to OSMRβ  binding30. In our initial efforts to express 
rhOSM, residues 1–187 of OSM were cloned into the plasmid pD441-NH (6-His-OSM), which has an amino 
terminal (N-terminal) tobacco etch virus (TEV) protease cleavage site (Fig. 1D). Expression of 6-His-OSM was 
tested in E. coli BL21(DE3) and BL21(DE3) pLysS cells grown in Lysogeny Broth (LB), minimal defined growth 
media (M9) or autoinduction medium. While cultures grew to high optical density  (OD600 = 4.0–4.5) follow-
ing induction with 1-thio-β-D-galactopyranoside (IPTG), the expression of 6-His-OSM was inconsistent and 
moderate at best. After examining a range of expression conditions (see Supplementary Information section 
“Expression optimization of 6-His-OSM” and Supplementary Figs. S1 & S2 for details) we hypothesized that 
the low yield of OSM was due to improper disulfide bond formation. Consequently, we tested OSM expression 
in Origami 2 pLysS and Shuffle cell lines, which are engineered with mutations in the thioredoxin and glu-
tathione reductase genes and can enhance disulfide bond formation in cytoplasmic expression of recombinant 
proteins. Consistent expression was observed when 6-His-OSM was expressed in both Origami 2 pLysS and 
SHuffle cell lines (Supplementary Fig. S1). However, the Origami 2 pLysS consistently yielded a lower final cell 
density (data not shown). Further, the Origami 2 pLysS strain is auxotrophic and would have required isotope-
enriched leucine supplementation for expression in minimal media, which would add a substantial cost to the 
protein  production34. These disadvantages of the Origami 2 pLysS made the SHuffle cell line the optimal choice 
of OSM expression for NMR.
To increase solubility, OSM residues 1–187 were cloned into the pD441-MBP (MBP-OSM) expression con-
struct, which contains an N-terminal TEV protease cleavage site. The combination of the SHuffle cell line and 
inclusion of the MBP solubility tag resulted in expression of increased soluble OSM, relative to the 6-His-OSM, 
as observed in SDS-PAGE (Supplementary Fig. S3). To further improve the yield of soluble OSM, we examined 
the effect of temperature on protein expression. Expression at 30 °C afforded higher yield of MBP-OSM relative 
to the expression at 18 °C (Supplementary Fig. S3) with no evidence of protein degradation even after a 20-h 
induction time. The final cell density was nearly twice as high with a 20-h induction relative to the 6-h induction. 
The expression of MBP-OSM with optimized conditions was scaled up to 1L growths in LB, 15N M9, and 13C, 
15N M9. Three chromatography steps (amylose affinity, ion-exchange, and size-exclusion chromatography) were 
essential to prepare highly pure rhOSM (Fig. 2, Supplementary Figs. S5–S10). The purification procedure yielded 
11.74 mg of rhOSM from 1 L of LB culture, 8.74 mg of 15N rhOSM from a 1L 15N M9 culture and 10.54 mg of 
13C, 15N OSM from a 1L 13C, 15N M9 culture that was consistently > 99% pure as assessed by SDS-PAGE (Fig. 2D). 
Expression and purifications on a smaller scale (100 mL cultures) were performed in triplicate and showed 
consistency and reproducibility of the reported expression and purification of rhOSM, although lower yield (ca. 
2–3 mg/L) was obtained from the 100 mL cultures (Supplementary Table 1).
Biological activity of rhOSM. Extracellular OSM primarily stimulates the JAK/STAT3 pathway through 
interactions with  OSMR22. To assess the biological activity of the rhOSM, phosphorylation at Tyr705 of STAT3 
(pSTAT3) was measured in T47D human breast cancer cells using both immunoblot analysis as well as an 
enzyme-linked immunosorbent assay (ELISA). The pSTAT3 expression induced at concentrations ranging from 
1.25 to 100 ng/mL rhOSM compared favorably with commercially available human OSM (chOSM), demonstrat-
ing similar efficacy at 25 ng/mL (Fig. 3A and Supplemental Fig. S11). As measured by ELISA, both rhOSM and 
chOSM induced significant pSTAT3 expression in T47D breast cancer cells compared to no treatment (Fig. 3B). 
Cells treated with chOSM displayed increased expression of pSTAT3 compared to rhOSM treated cells, the 
chOSM included additional 22 amino acids on the C-terminus that have been shown to preferentially bind to 
extracellular matrix molecules, potentially increasing the local concentration of the chOSM near the cell surface 
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Figure 2.  Expression and purification of rhOSM. (A) SDS-PAGE of amylose column purification of MBP-OSM, 
showing elutions E1-E5 and after cleavage with TEV. (B) SDS-PAGE of the load (L), flow-through (FT), and 
anion-exchange chromatography fractions. The fractions shown in gel were pooled and run over a size exclusion 
chromatography (SEC) column. (C) Chromatogram from SEC with rhOSM peak shown with bar. (D) SDS-
PAGE of gel fractions from the SEC peak.
Figure 3.  Recombinant OSM can effectively activate the STAT3 pathway in human breast cancer cell line, 
T47D. (A) T47D cells were untreated (NT), treated with commercial OSM (chOSM) or treated with increasing 
concentrations of recombinant OSM (rhOSM) for 30 min and levels of phosphorylated STAT3 (PSTAT3;Y705) 
were evaluated via immunoblot assay (representative blot from n = 2). pSTAT3 induction within cells treated 
with rhOSM show a similar trend to commercial OSM. Uncropped image shown in Supplemental Fig. S11. 
(B) Relative pSTAT3 expression in T47D breast cancer cells with no treatment (NT; white bar), or treatment 
with 25 ng/mL chOSM (black bar), or 25 ng/mL rhOSM (grey bar) over 30 min show significant increase in 
pSTAT3 levels detected via ELISA assay compared to NT and significance was observed between both treatment 
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of the adherent T47D cells, leading to a predictable slight increase in pSTAT3 induction from chOSM relative 
to rhOSM. The additional C-terminal 22 amino acids are unstructured and are not in proximity to site III, thus 
were not included in the rhOSM construct.
Secondary structure analysis by circular dichroism. Circular dichroism (CD) spectroscopy can be 
used to assess the secondary structure of proteins in solution and is useful as a quality control step in protein 
 production35. A CD spectrum of rhOSM showed that the purified protein was mostly alpha-helical with second-
ary structure contributions consisting of 56% helix, 8% sheet, 11% turn, and 26% unordered. This result was 
compared with a CD spectrum simulated using a structural model of human OSM generated from the crystal 
 structure28, which modeled in parts of the protein that were missing electron density (Fig. 4). The predicted 
secondary structure contributions from the structural model were 61% helix, 0% sheet, 10% turn, and 28% unor-
dered with an RMSD of the experimental to the simulated spectrum of 0.66. The experimental and simulated 
spectra are in close agreement, suggesting the rhOSM has a secondary structure closely resembling the OSM 
crystal structure.
Mass spectrometry analysis of rhOSM. The sequence and disulfide pattern of rhOSM was analyzed 
by mass spectrometry. Purified rhOSM was subjected to tryptic digestion in the presence and absence of 
2-iodoacetamide (IAA). Alkylation of free cysteine thiols with IAA results in an S-acetamide derivative that adds 
57 mass  units36, which allows for detection of free thiols by comparing the untreated sample with the alkylated 
sample. The resulting peptide fragments were detected by MALDI-TOF mass spectrometry, and mass-to-charge 
(m/z) values of the resulting peptide ions were analyzed. The sequence coverage was 96% in the absence and 91% 
in the presence of IAA (Supplementary Fig. S12). The highest intensity peak in the absence of IAA (1743.0 m/z) 
was identified as the peptide 69-GFLQTLNATLGCVLHR-84 (Supplementary Fig.  S13 and Table  S2). In the 
IAA treated sample, the highest intensity peak shifted to 1799.9 m/z (Supplementary Fig. S14 and Table S3), 
consistent with the expected + 57.0 Da mass shift with the addition of the S-alkylated acetamide derivative at 
Cys80. A confirmative set of peaks at 1899.1 m/z and 1965.1 m/z were identified as the unmodified and an 
S-alkylated acetamide derivative at Cys80 of fragment 68-RGFLQTLNATLGCVLHR-84. Several peaks heavier 
than 2200 m/z were observed in the untreated sample and could be assigned to Cys6-Cys127 and Cys49-Cys167 
disulfides but could not be discriminated from combinations of peptides that also could have contained the 
Cys80 residue. All of the expected disulfide peptides (> 2000 m/z) were low intensity in the untreated sample, 
and none were observed in the IAA treated sample (maximum detected peak was 2480.3 m/z). This suggests 
that the higher m/z peaks were due to interaction between cysteine containing peptides and the free Cys80 dur-
ing ionization and were not necessarily representative of interactions in solution. A similar observation of low 
intensity or missing peptides that should have indicated proper disulfide formation in OSM has been reported 
 before37.
Figure 4.  Circular dichroism spectrum shows rhOSM secondary structure is consistent with X-ray structure. 
An experimental spectrum of rhOSM (solid, black) is compared to a simulated spectrum (dashed, black) 
derived from a model of the X-ray crystal structure with the flexible Loop AB that was missing electron density 
in the crystal structure modeled in. Residuals between the experimental and simulation data (grey) are low at 
higher wavelengths but increase at lower wavelengths due to solvent scattering.
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Optimization of buffer conditions for structural studies. In vitro solution studies of rhOSM, includ-
ing NMR, require a protein to behave as a homogeneous, stable solute. Specifically, for NMR experiments, a 
phosphate buffered system is preferred over protonated buffer components and additives, which potentially 
distort the spectra, making interpretation more challenging. We used differential scanning fluorimetry to screen 
additives in a phosphate buffer that would increase the thermal stability of rhOSM. Various amino acid and poly-
amine additives were investigated using an established  approach38. The denaturation profile of rhOSM in sodium 
phosphate buffer with and without additives exhibited low fluorescence at room temperature, indicative of a 
well-folded protein (Fig. 5A). All additives except L-arginine showed a noticeable stabilization of rhOSM. Imi-
dazole, L-histidine, L-glutamine, L-proline, and a combination of L-arginine and L-glutamate equally increased 
melting temperature from 54 ºC to 59 ºC (Fig. 5B and Table 1). The L-arginine and L-glutamate combination 
is known to prevent protein aggregation and precipitation, increasing long-term stability, and protecting pro-
tein samples from proteolytic  degradation39. We observed a decrease in proteolysis of rhOSM with L-arginine 
and L-glutamate relative to no additive (Supplementary Fig. S15). Moreover, it has been demonstrated that the 
presence of these amino acids does not interfere with protein–protein  interactions39, thus we chose to use the 
L-arginine and L-glutamate combination in NMR experiments.
To assess the effect of the additives on the structural stability of rhOSM, a 1H, 15N heteronuclear single quan-
tum correlation (HSQC) NMR spectroscopy was collected. Spectra were recorded in a 50 mM sodium phosphate 
buffer, pH 6.6; without and with 50 mM L-arginine and 50 mM L-glutamate additive (Fig. 6). Both spectra show 
dispersed, resolved peaks, indicative of a well-folded protein, however, the optimized buffer conditions using 
50 mM L-arginine and 50 mM glutamate displayed increased signal to noise ratio across the spectrum (Fig. 6). 
The addition of L-arginine and L-glutamate allowed for detection of several peaks that were not observable in 
the absence of the additive (Fig. 6). Overall, the spectral quality was increased in the presence of L-arginine and 
L-glutamate.
Small molecule inhibitor titrations. After identifying optimal solution conditions for 1H, 15N HSQC 
NMR experiments with 15N rhOSM, we focused our efforts toward assessing the utility of this construct in a 
structure-based drug design approach to target OSM. Upon titration of an isotopically enriched protein with a 
Figure 5.  Additives increase the thermal stability of rhOSM in pH 6.6 phosphate buffer. (A) Thermal 
denaturation curves with legend. Curve with sodium phosphate buffer only (None), shown in black; L-arginine 
and L-glutamate in dashed black; L-proline in sage; L-glutamine in salmon; L-histidine in gray; imidazole in 
peach; and L-arginine in orange. (B) The first derivative of fluorescence emission as a function of temperature.
Table 1.  Summary of the melting temperatures for the largest amplitude peak from the sum of two Gaussians 
fit to the first derivative of fluorescence with respect to temperature for each of the additive conditions.
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ligand of sufficient binding affinity, changes in the local magnetic environment of backbone amide bonds (N–H) 
give rise to characteristic chemical shift perturbations (CSPs)40. If backbone N–H correlation resonances are 
assigned, this assay allows for identification of interacting residues at the small molecule/protein interface and 
assignment of putative binding modes. Further, nonlinear regression analysis of the magnitude of the CSPs plot-
ted against concentration of small molecule delivered may be used to determine a binding affinity measured as 
the dissociation equilibrium constant (Kd) for the small molecule inhibitor (SMI).
Here, we chose to test the NMR assay using rhOSM and a preliminary inhibitor identified from a previous 
screen (unpublished). Briefly, a small molecule inhibitor site was identified that was expected to directly block 
protein–protein interactions with the OSMRβ subunit at site III. A virtual library consisting of ~ 1.6 million 
 compounds41,42 was screened and prioritized based on their predicted binding energy potential to binding sites 
(unpublished). The top 26 candidates were purchased and tested in vitro for inhibition of OSM-induced phos-
phorylation of STAT3 (unpublished). Lead compound OSM-SMI-10 was identified as the most potent inhibitor of 
 pSTAT343. OSM-SMI-10B (Fig. 7A,), a derivative of OSM-SMI-10 (patent pending) was subsequently synthesized 
and identified as a hit based on its ability to significantly reduce OSM-induced STAT3 phosphorylation in cancer 
cells upon co-incubation with OSM as measured by  ELISA44. Supplementary Information section “Chemistry” 
provides details regarding the synthesis of OSM-SMI-10B. Characterization of intermediates and final product 
Figure 6.  Optimized buffer conditions improve the quality OSM NMR spectrum. 1H, 15N HSQC spectrum of 
100 μM 15N-labeled OSM in 50 mM sodium phosphate, 100 mM sodium chloride, pH 6.6. Zoomed regions of 
interest from the 1H,15N HSQC spectrum and projection along the 15N axis of 100 μM 15N-labeled OSM with 
no additive (left) and with 50 mM L-arginine, 50 mM L-glutamate (right). Spectra were collected with identical 
parameters, processed the same and plotted at the same contour levels.
Figure 7.  OSM-SMI-10B docked to OSM. (A) Chemical structure of OSM-SMI-10B. (B) OSM-SMI-10B 
(green and red) docked into a groove found at Site III on OSM (surface contour, grey).
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are shown in Supplemental Scheme 1 and Figs. S16–S2. OSM-SMI-10B was chosen for this study to demonstrate 
the utility of an NMR based screen to optimize the structure-based drug design approach to inhibit OSM.
OSM-SMI-10B was computationally docked into Site III (Fig. 7B), which is considered the interaction site 
for OSMRβ. To determine if the decrease in OSM activity was the result of direct binding to OSM and to iden-
tify the OSM-SMI-10B binding site, 15N rhOSM was titrated with increasing concentration of OSM-SMI-10B 
(Fig. 8A–C). Significant CSPs were observed for multiple peaks. The four peaks with the largest CSPs were 
selected and analyzed using the quadratic expansion of the isotherm binding model to obtain a Kd of 12.2 ± 
3.9 μM. Given the experimental conditions, the calculated Kd is an estimate of an upper limit of the binding 
affinity. The peaks used for fitting were tentatively assigned to Asp87, Gln90, Arg91, and Leu92 by comparing 
the minimal chemical shift differences between rhOSM and a glycosylated version of hOSM for which peak 
assignments  available45. Additional assignments were not possible due to differences in primary sequence and 
post-translational modifications. Notably, Asp87, Gln90, Arg91, and Leu92 are all located near OSM binding 
site III (Fig. 8D), where OSM is thought to interact with the OSMRβ  subunit28. The Kd was further validated 
with a fluorescence quenching assay, which yielded a Kd of 10.37 ± 0.81 μM (Supplemental Figs. S24 & S25). A 
comparison of the NMR and fluorescence quenching experiments to two additional SMI compounds is shown 
in Supplementary Figure S25A. OSM-SMI-10B11 is a derivative of OSM-SMI-10B and OSM-SMI-27A6 is 
chemically unique SMI, synthesized based on QSAR and computational modelling. The binding affinities were 
similar between OSM-SMI-10B and OSM-SMI-10B11 and the corresponding CSPs had a similar pattern (Sup-
plementary Figure S25C). OSM-SMI-27A6 was twofold weaker in affinity and showed fewer CSPs common to 
the other two SMIs. However, due to insolubility, the maximum titration point for OSM-SMI-27A6 was only 
Figure 8.  SMI titration of 15N rhOSM monitored by NMR spectroscopy. (A) An overlay of 1H, 15N HSQC 
NMR spectra of 100 μM 15N-labeled OSM with cross peaks color-ramped from red to blue with increasing SMI 
concentration from 20 μM (red) to a final concentration of 220 μM (blue). A DMSO control is shown in black. 
(B) Zoomed regions of panel A for Asp87, Gln90, Arg91, and Leu92. (C) A saturation binding curve was fit to 
the CSP vs. SMI for peaks that were tentatively assigned to Asp87, Gln90, Arg91, and Leu92. (D) OSM oriented 
with Site III in view with protruding Phe160 and Lys163 residues (shown as sticks and colored gold), which 
make up an FXXK motif in binding site. The side chains of residues Asp87, Gln90, Arg91, and Leu92, which 
show significant CSPs are shown as sticks and labeled.
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80 μM Supplementary Figure S25D. This comparison highlights the utility of NMR to validate direct binding 
of SMIs to target proteins.
Discussion
The role of OSM in multiple inflammatory diseases including fibrotic diseases, arthritis, and numerous types 
of cancers has led to significant interest in attenuating OSM cell signaling as a potential therapeutic. Despite 
advances in biological therapies such as monoclonal antibodies to inhibit OSM, there are no FDA-approved anti-
OSM drugs. Moreover, there have been no reports of small molecules that specifically bind to and inhibit OSM. 
This is presumably due to the fact that OSM exerts its biological activity through protein–protein interactions 
(PPIs), which are notoriously difficult to disrupt with small molecules. PPIs are generally characterized by large, 
flat, discontinuous, and hydrophobic binding interfaces that are not well-suited for high specificity and affinity 
small molecule  binding46. Though targeting PPIs has been a major challenge in drug discovery, structure-based 
NMR experiments have become essential to targeting these interactions that were once thought to be “undrug-
gable”47. For example, using NMR screening and structure-based drug design, highly potent small molecule 
inhibitors of Bcl-2 family protein–protein interactions were  discovered33 that eventually led to the development 
of FDA-approved Bcl-2 inhibitor ABT-199 (Venetoclax)48. This serves as an important proof-of-concept that 
PPIs can be targeted using NMR-based approaches, and such inhibitors are amenable to clinical development. 
Further, interactions between Interleukin-2 (IL-2)/Interleukin-2 receptor alpha subunit (IL-2Rα) and their dis-
ruption by small molecules were previously studied using NMR  techniques49. These structure-based methods 
require soluble, functional proteins at high yield, and as such this effort is essential to pursuing structure-based 
drug discovery efforts for targeting OSM.
There are reports of recombinant expression of human OSM, but previous methods had either low yields, 
low purity, or inhomogeneous protein. For example, a 6-His tagged OSM was expressed in E. coli BL21(DE3) 
but required refolding in the presence of glutathione reductase to facilitate proper disulfide bond formation. 
Though this protocol allowed for a one-step purification using immobilized metal affinity chromatography, 
OSM was obtained in relatively low yield (2 mg/L culture)50. Soluble recombinant OSM was produced via a 
GST-fusion in the E. coli JM109 strain, though purification details and yield were not  included51. Recombinant 
OSM was similarly expressed for crystal structure determination via GST-fusion in E. coli JM109, consisting 
of residues 1–187 with four extra residues (GPGS) corresponding to a 3C protease cleavage site. The OSM was 
reportedly greater than 80% pure as determined by SDS-PAGE after purification, but again yields were not 
 included28. Isotope enriched OSM was previously produced for solution NMR studies. However, this protocol 
involved expression from yeast Saccharomyces cerevisiae, C80A/N30A/N192A mutations, a non-native FLAG 
(FYDDDDK) affinity tag appended to the N-terminus, and post-translational modifications that resulted in a 
heterogeneous mixture; together complicating resonance  assignment45. Though the mutated OSM construct was 
shown to have similar activity to radiolabeled native OSM in a competitive LIFR binding assay, it is unclear if the 
mutations have deleterious effects on the ability of OSM to bind to the OSMR and thus activate OSM-specific 
cell signaling pathway, as this was untested.
Here, we report successful production of recombinant unlabeled, 15N labeled, and 13C, 15N labeled rhOSM 
in milligram quantities with excellent purity (≥ 99%). The identity, purity and bioactivity of the rhOSM was 
fully characterized and the rhOSM concentration-dependent induction of pSTAT3 was similar to chOSM, as 
measured by immunoblot and enzyme-linked immunosorbent assays. Optimized buffer conditions enabled 
collection NMR spectra from both 15N and 13C, 15N labeled rhOSM samples with dispersed and well-resolved 
peaks, which indicate that the rhOSM is properly folded. Importantly, inhibition of OSM-driven pSTAT3 pro-
duction by a small molecule and NMR titrations lay the groundwork for an NMR-based drug design approach 
to targeting OSM. Our protocol is similar to Nguyen et al., who used a maltose binding protein (MBP) fusion 
construct and expression in E. coli  SHuffle37, which we independently also found. A notable distinction in our 
study is the bioactivity test. Nguyen et al. tested their recombinant human OSM for activity by in vitro inhibition 
of Th17 mouse cell differentiation. Critically, human OSM shares only 48.9% sequence identity with mouse OSM 
(mOSM) where differences within the AB loop of OSM determine species-specific  activities31. Although hOSM 
is able to activate mouse LIFR (mLIFRα/gp130), hOSM and mOSM display no cross-species signaling to OSMR 
despite their structural  similarities22,52. We used the T47D human breast cancer cell line for the bioactivity assay, 
which we feel is a more appropriate cell line for small molecule lead optimization screening.
Reports of small molecules with anti-OSM activity are scarce, both in the journal and patent  literature43. 
Members of the ansamycin family of antibiotic microbial secondary metabolites were shown to potently inhibit 
OSM and IL-6 driven secreted placental alkaline phosphatase (sPAP) production in HepG2B6 cells while hav-
ing little to no effect on TNFα sPAP production. However, the ability of the same compounds to inhibit protein 
synthesis and lymphocyte production suggested their biological activities were non-specific and were unlikely 
to be attributable to direct inhibition of OSM or IL-653. N-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzamide was 
similarly shown to suppress OSM driven sPAP production in HepG2B6 cells with limited inhibition of TNFα 
driven sPAP production, but it is unclear if this activity is attributable to specific interaction with OSM, as this 
was otherwise  untested54. Though these studies potentially identified promising lead compounds for attenuating 
OSM signaling, the methods employed were unsatisfactory for inhibition was due to direct interaction of small 
molecules with OSM. This issue is compounded by the high structural similarity of OSM with other cytokines 
in its family, namely IL-6 and LIF. The development of anti-OSM therapeutics without careful analysis of specific 
OSM/SMI interactions would likely have significant cross-reactivity with these cytokines. In an effort to alleviate 
these potential issues, we sought to develop a reliable methodology for directly measuring OSM/SMI interactions.
NMR-based experiments are important tools for drug discovery and design and have been used to elucidate 
structure–activity relationships and develop high-affinity small molecule  ligands32, fragment-based screening 
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and drug  design55, high-throughput screening and determination of binding  affinity56, and mapping important 
binding interactions of target  proteins40 and small molecule  ligands57. Here, we utilized 1H, 15N NMR chemical 
shift perturbation experiments to confirm direct binding of a small molecule inhibitor of OSM-driven phos-
phorylation of STAT3. Several peaks in the 1H, 15N NMR spectrum with chemical shift perturbations were 
tentatively assigned to residues in binding site III of OSM, where OSM interacts with the OSM-specific OSMRβ. 
This is the first report of a small molecule confirmed to modulate OSM activity through direct binding to OSM. 
These findings suggest that small molecules can be used to specifically target the OSM-OSMRβ interaction with 
biologically relevant affinities (Kd ≈ 10 μM). The isotopically enriched rhOSM produced using our methodol-
ogy will enable NMR-based experiments for further characterization of OSM-small molecule interactions that 
will inform iterative optimization of the SMIs. Current efforts are underway in our lab to obtain full backbone 
and side chain chemical shift assignments for rhOSM. We envision that using our optimized bioactivity assay 
in combination with NMR chemical shift perturbations will enable a structure-based drug design approach for 
targeting OSM that could eventually lead to a useful therapeutic option for treatment of OSM-related illnesses.
Methods
Reagents. Unless otherwise mentioned, chemical reagents were purchased from Fisher Scientific (Waltham, 
MA). Isotopically enriched reagents were purchased from MilliPoreSigma (St Louis, MO).
Plasmid constructs. 6-His-OSM and MBP-OSM constructs were purchased from ATUM (Newark, CA), 
amplified in DH5α E. coli chemically competent cells and purified using a PureLink Quick Plasmid Miniprep 
kit; both from Invitrogen (Carlsbad, CA).
Recombinant OSM expression. Freshly transformed chemically competent Shuffle E. coli cells were used 
to inoculate 10 mL LB containing appropriate antibiotics at 30 °C, overnight, shaking at 220 rpm. The overnight 
culture was used to inoculate 1 L cultures appropriate antibiotics at starting  OD600 = 0.05–0.10. Media was either 
LB, M9 supplemented with (≥ 98 atom %) 15N ammonium chloride and 0.5 g/L 15N Isogro, or (≥ 98 atom %) 15N 
ammonium chloride, (≥ 99 atom %) 13C glucose and 0.5 g/L 15N, 13C Isogro). The low level of labeled algal lysate 
(Isogro) is included to decrease the time to induction (see Supplementary Fig. S4). The cells were grown at 37 °C 
with shaking to  OD600 = 0.6–0.8. Expression was induced with 1 mM IPTG and cultures were grown for 20 h at 
30 °C with shaking. Cells were harvested by centrifugation, suspended in Lysis Buffer and stored at − 20 °C until 
purification.
Purification of recombinant OSM. Frozen re-suspended cells were thawed and immediately disrupted 
by sonication in an ice-salt bath. The lysate was clarified by centrifugation and filtered through a 0.4 micron 
syringe-driven filter. The cleared lysate was loaded onto a pre-equilibrated amylose resin (New England BioLabs, 
Ipswich, MA), and the flow through was collected. The column was washed with Binding Buffer (20 mM Tris–Cl, 
200 mM sodium chloride, 1 mM EDTA, 1 mM DTT, pH 7.4), then eluted with a linear gradient of elution buffer 
(Binding Buffer with 10 mM maltose). Eluted MBP-OSM was cleaved with TEV protease (1 mg of TEV pro-
tease per 100 mg of MBP-OSM) overnight at room temperature in 50 mM sodium phosphate, 100 mM sodium 
chloride, 0.5 mM EDTA, 1 mM DTT, pH 7.5. TEV protease is prepared in-house using a standard protocol. The 
resulting solution was then dialyzed into a lower salt buffer (50 mM sodium phosphate, 10 mM sodium chlo-
ride, pH 7.5) and applied to Macro-prep High S resin (Bio-Rad, Hercules, CA) and eluted with a linear sodium 
chloride gradient to remove cleaved MBP and TEV. Fractions containing OSM were identified by SDS-PAGE, 
combined, and concentrated. The sample was filtered using a 10 μm spin column and subjected to size-exclusion 
chromatography (Superdex S75 16/60; Cytiva, Marlborough, MA) in a buffer containing 50 mM sodium phos-
phate, 100 mM sodium chloride, 1 mM DTT, pH 6.6. Fractions containing OSM were identified from the chro-
matogram and confirmed by SDS-PAGE. The concentration of purified OSM was determined spectroscopically 
at 280 nm using the calculated extinction coefficient of 11,460  M−1⋅cm−1.
SDS‑PAGE. Aliquots of pre-induced and post-induced cells were taken in an amount corresponding to 
 OD600 = 0.8 in 1 mL, pelleted and boiled in 100 μL SDS-PAGE Sample Buffer containing 10% (v/v) 2-mercap-
toethanol prior to gel electrophoresis. Aliquots from chromatography samples were diluted fourfold in Sample 
Buffer and boiled prior to gel electrophoresis. Samples were run on NuPAGE 4–12% Bis–Tris gels (ThermoFisher 
Scientific, Waltham, MA) and stained with SimplyBlue SafeStain (ThermoFisher Scientific, Waltham, MA). Gel 
images were collected with a FluorChem R imager (ProteinSimple, Santa Clara, CA). Protein expression and 
percent purity were quantified from gel images using ImageJ (http:// imagej. nih. gov/ ij).
Bioactivity assays. Cell lines. The human T47D breast cancer cell line was purchased from the American 
Type Culture Collection (Rockville, MD, USA) and cultured using RPMI 1640 media supplemented with 10% 
Fetal Clone III synthetic serum (HyClone Cytiva, Marlborough, MA; Cat# SH30109.3) and 100 units/mL peni-
cillin/streptomycin. All cells and experimental incubations were maintained at 37 °C, 5% carbon dioxide, and 
100% humidity within a water-jacketed cell culture incubator.
Immunoblot analysis. T47D cells were plated on 24-well plates at 70–75% confluency and allowed to adhere 
overnight. Cells were serum starved with serum-free RPMI media for 4 h and subsequently treated with either 
commercially available recombinant human OSM (chOSM) (PeproTech, Rocky Hill, NJ; Cat# 300-10  T) or 
rhOSM at specified concentrations for 30 min. Afterwards, cell lysates were collected with 1X Cell Lysis Buffer 
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(Cell Signaling Technology, Danvers, MA; Cat# 7018). Lysates were run on an SDS-PAGE gel and transferred 
onto a nitrocellulose membrane via semi-dry transfer. Blots were rinsed in  ddH2O and allowed to dry completely 
before being blocked with LiCor Odyssey PBS blocking buffer (LiCor, Lincoln, NE; Cat# 927-4000) for 1 h. After 
blocking, primary antibodies (1:1000) suspended in blocking buffer were applied to the membrane, shaken for 
1 h at room temperature, and incubated overnight at 4 °C. Membranes were then washed 6 × 5 min with 1X PBS 
supplemented with 0.5% Tween and secondary antibodies (1:15,000) suspended in blocking buffer were applied 
for 45 min. A final wash step of 6 × 5 min with PBS-T, membranes were imaged at 700 nm using the LiCor Odys-
sey CLx imaging system. Antibodies: phospho-STAT3 (Y705) (Cell Signaling Technology, Danvers, MA; Cat# 
9145), beta-Actin (Cell Signaling Technologies; Cat# 3700), donkey anti-rabbit IRDye 800CW (LiCor, Lincoln, 
NE; Cat# 925-32213).
Enzyme linked immunosorbent assay (ELISA). T47D cells were plated as on 24-well plates at 70–87% conflu-
ency and allowed to adhere overnight at 37 °C. Following overnight incubation, cells were serum starved with 
serum free RPMI media for 4 h and subsequently treated with 25 ng/mL chOSM (PeproTech, Rocky Hill, NJ; 
Cat# 300-10 T) or rhOSM at 25 ng/mL for 30 min. Afterwards, lysates were collected as previously described for 
 immunoblot20. Lysate samples were diluted 1:4 in 1X PBS supplemented with 1% BSA. Levels of phospho-STAT3 
were detected using the PathScan Phospho-STAT3 (Y705) Sandwich ELISA kit (Cell Signaling Technologies; 
Cat# 7300) as per manufacturer’s instructions. Relative expression was quantified comparing non-treated and 
rhOSM treated samples to chOSM levels. Experiments were run in triplicate and data was analyzed using Micro-
soft Excel and Prism 8 (v. 8.2.1, GraphPad Software).
Circular dichroism. Purified rhOSM was exchanged into 50 mM sodium phosphate buffer, pH 6.6, contain-
ing 100 mM NaF, and 1 mM TCEP on an S75 column. CD spectra were collected using a Jasco J-810 spectropo-
larimeter (JASCO). Purified rhOSM was measured at 0.197 mg/mL in a 0.1 cm cuvette at 25 °C for far-UV scans 
(275–170 nm). The background subtracted CD spectrum of rhOSM and �ε was calculated using the equation:
where θ = machine unit output, mean residue weight (MRW) = protein mean weight (daltons)/number of resi-
dues, path length (P) = cuvette path length in cm, protein concentration (CONC) = protein concentration in mg/
mL, and [θ] = 3298 Δε. The resulting spectrum was then analyzed using the DichroWEB  server58. The CDSSTR 
method with SP175 reference dataset were used to calculate the secondary structure contributions to the CD 
 spectrum59 A structural model of OSM was generated using Swiss-MODEL60 to account for residues in the AB 
Loop that were missing from the crystal structure  (1EVS28). A CD spectrum was simulated using the coordinates 
of the resulting model with the software  PDB2CD61.
Mass spectrometry. Purified rhOSM (30 μg) was diluted in Tris buffer (50 mM, pH 8.0), followed by the 
treatment with 1,4-dithiothreitol (DTT, 10 mM) to reduce disulfide bonds and iodoacetamide (IAA, 55 mM) 
for alkylation and then digested with trypsin (trypsin to protein ratio 1:30) at 37 °C overnight. In a separate 
experiment, purified rhOSM (30 μg) was digested directly with trypsin under the same conditions but without 
the treatment with DTT and IAA. Mixtures of resulting peptides was desalted using a Pierce C18 spin column 
(ThermoFisher Scientific, Waltham, MA), dried in a vacuum centrifuge, and reconstituted in water containing 
0.1% trifluoroacetic acid (TFA). One μL of the peptide solution was mixed with one μL of saturated α-Cyano-4-
hydroxycinnamic acid solution in 50% acetonitrile and 0.1% TFA. One μL of the mixture was then applied to a 
ground stainless steel MALDI target and allowed to air dry. Spectra of the peptides were acquired on a Bruker 
autoflex MALDI TOF mass spectrometer in reflector mode. The masses were analyzed using Protein Prospector 
v 5.24.0 (http:// prosp ector. ucsf. edu/ prosp ector/ mshome. htm). Data were compared to theoretical masses from 
 PeptideMass62 with allowance of one missed Trypsin cleavage.
Differential scanning fluorimetry. rhOSM (560 μL, 33 μM) was incubated with 1 μL of SYPRO Orange, 
5000X in DMSO (Invitrogen), thoroughly mixed and divided between eight vials. Concentrated stock solution 
of each additive was diluted to the final concentrations shown in Table 1. Each solution was loaded 3 × 20 μL 
into a 96-well clear reaction PCR microplate. The microplate was sealed with an adhesive optical clear seal and 
centrifuged at 500 × g for 2 min at room temperature. Data were collected on a QuantStudio3 qPCR system 
(Applied Biosystems). Samples were equilibrated at 25 °C for 5 min before starting a temperature ramp of 1 °C/
min over a temperature range from 25 °C to 95 °C. Fluorescence readings were recorded every 1 min. Accord-
ing to the described  protocol38 raw data were truncated in Excel to remove post-peak quenching, then analyzed 
and fit using a nonlinear Gauss equation in Prism 8 (v. 8.2.1, GraphPad Software). The thermal denaturation 
temperatures  (Tm) of rhOSM screened with buffer additives were determined by fitting a sum of two Gaussians 
to the time derivative of fluorescence. The  Tm for each buffer condition is reported for the Gaussian fit with the 
maximum amplitude.
Molecular docking. Molecular docking was performed using AutoDock  Vina63. The human OSM protein 
structure (PDB ID: 1EVS) was used as the “receptor” model. The OSM structure was minimized using sequential 
steepest descent and conjugate gradient algorithms. OSM-SMI-10B was docked against OSM at Site III using a 
rigid receptor model, grid point spacing of 0.375 A, and exhaustiveness of 8. Predicted binding affinities were 
calculated using the default weighting for the AutoDock Vina scoring function.
�ε = θ ×
0.1×MRW
P × CONC × 3298
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NMR spectroscopy. All NMR experiments were conducted in 50 mM sodium phosphate (pH 6.6), 100 mM 
sodium chloride, 5%  D2O (NMR buffer) with 500 μL of sample in a 5 mm NMR tube unless otherwise noted. 
Spectra were recorded at 298 K on a Bruker AVANCE III 600 MHz spectrometer equipped with a 5 mm TCI 
cryoprobe with z-axis gradients. 1H, 15N HSQC spectra were collected with the Bruker pulse program hsqcfp-
f3gpphwg64. Spectra were processed with Topspin 3.2 (Bruker, Billerica, MA),  NMRPipe65 and plotted using 
 NMRglue66. For buffer optimization studies, HSQC spectra were taken of 100 μM 15N OSM in NMR buffer 
and in NMR buffer supplemented with 50  mM L-arginine, 50  mM L-glutamate. Samples were filtered with 
10-micron spin filter prior to loading into NMR tube.
For small molecule inhibitor (SMI) titrations, 500 μL of a 100 μM sample of 15N OSM in NMR Buffer was 
titrated with a 20 mM stock solution of OSM-SMI-10B in  d6-dimethyl sulfoxide. The SMI stock solution was 
added in 1 μL increments from 20 μM to a final concentration of 220 μM total OSM-SMI-10B. An additional 
100 μM sample of 15N OSM was prepared with 8 μL  d6-dimethyl sulfoxide as a control. The four peaks with the 
largest chemical shift perturbations (CSPs) were subjected to binding analysis using the difference in chemical 
shift of both 15N and 1H40. Combined CSPs for the four selected peaks were then plotted against the concentra-
tion of SMI delivered and fit to a saturation binding model, given by:
where �δ is the change in chemical shift upon addition of ligand, [P] is the concentration of rhOSM, [L] is the 
concentration of ligand delivered, and �δmax is the maximum chemical change upon saturation of rhOSM with 
ligand. Curve fitting and error analysis was performed using Wolfram Mathematica to obtain a dissociation 
constant (Kd).
Fluorescence quenching. Fluorescence quenching measurements were made in triplicate solutions of 
1 µM rhOSM (100 mM sodium chloride, 50 mM sodium phosphate, 0.1 mM DTT, pH 6.6) and titrated with 
approximately 5 µM increments using a 1.875 mM small molecule stock solution in DMSO. An additional 1 µM 
rhOSM solution was titrated with equivalent volumes of DMSO to account for changes in fluorescence due to 
dilution and solvent effects. A total of 16 titration points were collected not to exceed 5% (v/v) total DMSO. The 
SMI absorbance peaks were all less than 280 nm and did not absorb light at either the excitation or tryptophan 
emission wavelengths, so there was no need to correct for inner filter effects.
Fluorescence measurements were made on a Cary Eclipse spectrofluorometer equipped with a Xe arc lamp. 
Fluorescence intensities were measure by exciting 280 nm (4 nm slit width) and recording the emission from 
345 to 355 nm with a photomultiplier tube voltage of 700 V. The fluorescence at each titration point was corrected 
by adding the decrease in fluorescence intensity caused by dilution with DMSO and normalized (f) to the fluo-
rescence intensity in the absence of small molecule (f0). The average value of the three replicates for each point 
was plotted against concentration of small molecule delivered, and fit to a Stern–Volmer, modified Stern–Volmer, 





+ (1− fa) , originally described by Charlier et al.67, 
where ff0 is the fluorescence signal of OSM with SMI divided by the fluorescence signal of the blank, fa is the fraction of accessible fluorescence, [X] is the concentration of the SMI, and the dissociation constant (Kd). Kd 
values were obtained from a least squares regression fitting routine and errors are reported as the standard error 
of the fit with a symmetrical 95% confidence interval. Raw data were analyzed using Microsoft Excel and all 
curve fitting analyses were performed in Prism 8 (v. 8.2.1, GraphPad Software).
Data availability
The datasets generated during and/or analysed during the current study are either available in the supplemental 
information or from the corresponding author on reasonable request.
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